We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00370721
Recruitment Status : Unknown
Verified June 2008 by Shahid Beheshti University of Medical Sciences.
Recruitment status was:  Recruiting
First Posted : September 1, 2006
Last Update Posted : June 26, 2008
Information provided by:

Study Description
Brief Summary:
To evaluate the effect of intravitreal bevacizumab on the course of diabetic retinopathy in cases with the signs of active progressive PDR

Condition or disease Intervention/treatment Phase
Diabetic Retinopathy Drug: bevacizumab Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : March 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: I Drug: bevacizumab

Outcome Measures

Primary Outcome Measures :
  1. Regression of diabetic retinopathy
  2. visual acuity

Secondary Outcome Measures :
  1. neovascularization
  2. fibrous proliferation
  3. traction retinal detachment
  4. vitreous hemorrhage
  5. pan retinal photocoagulation

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cases of active progressive PDR with history of scatter laser photocoagulation

Exclusion Criteria:

  • history of vitrectomy
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00370721

Contact: Hamid Ahmadieh, MD +98 21 22585952 hahmadieh@hotmail.com

Iran, Islamic Republic of
Hamid Ahmadieh, MD Recruiting
Tehran, Iran, Islamic Republic of, 16666
Contact: Hamid Ahmadieh, MD    +98 21 22585952    hahmadieh@hotmail.com   
Sponsors and Collaborators
Shahid Beheshti University of Medical Sciences
Principal Investigator: Hamid Ahmadieh, MD Ophthalmic Research Center of Shaheed Beheshti Medical University
More Information

ClinicalTrials.gov Identifier: NCT00370721     History of Changes
Other Study ID Numbers: 8538
First Posted: September 1, 2006    Key Record Dates
Last Update Posted: June 26, 2008
Last Verified: June 2008

Keywords provided by Shahid Beheshti University of Medical Sciences:
Proliferative diabetic retinopathy(PDR)
Pan retinal photocoagulation (PRP)
Vitreous hemorrhage
Traction retinal detachment
Neovascularization on disc (NVD)
Neovascularization elsewhere (NVE)
Fibrous proliferation on disc (FPD)
Fibrous proliferaiton elsewhere (FPE)

Additional relevant MeSH terms:
Retinal Diseases
Diabetic Retinopathy
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents